Phillips-Medisize Expands - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Phillips-Medisize Expands

Phillips-Medisize, an outsource provider of design and manufacturing services for medical devices and drug delivery markets, reports the start of production and completion of the 60,000-ft2expansion to its Kontiolahti, Finland site. Production has already begun and will continue to ramp up several new programs before the first of the year. The site focuses on the industrialization and production of inhalers, insulin pens, transfer devices, and syringes.

The expansion includes 12,900 ft2 of Class 8 clean-room manufacturing and assembly and has space for the additional expansion for molding machines and assembly. New high-speed automation lines enable the ramp up of multi-component, complex drug-delivery devices from prototype to high-speed automated 24/7 mass production under competitive cost-structure. Total Kontiolahti numbers now include, multiple high-speed, fully automated assembly lines, fully automated printing lines, and several semi-automated lines.

Source: Phillips-Medisize


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here